(Q83186748)
Statements
Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients (English)
Robert W Schrier
William T Abraham
Alireza A Shamshirsaz
Kim McFann